Amgen Full Year 2024 Earnings: EPS Misses Expectations

Amgen (NASDAQ:AMGN) Full Year 2024 Results

Key Financial Results

• Revenue: US$33.4b (up 19% from FY 2023).
• Net income: US$4.09b (down 39% from FY 2023).
• Profit margin: 12% (down from 24% in FY 2023).
• EPS: US$7.62 (down from US$12.56 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Amgen EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%.

The primary driver behind last 12 months revenue was the United States (U.S.) segment contributing a total revenue of US$23.3b (70% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$6.78b (36% of total expenses). Explore how AMGN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 9.3% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Amgen (1 is a bit concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.